HIVE vs GEMI

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

HIVE

70.4
AI Score
VS
HIVE Wins

GEMI

61.1
AI Score

Investment Advisor Scores

HIVE

70score
Recommendation
BUY

GEMI

61score
Recommendation
BUY

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HIVE GEMI Winner
Revenue 164.00M 95.75M HIVE
Net Income -221.61M -216.70M GEMI
Net Margin -135.1% -226.3% HIVE
ROE -60.8% -46.3% GEMI
ROA -25.8% -14.4% GEMI
Total Assets 857.69M 1.50B GEMI
Cash 138.99M 188.62M GEMI
Current Ratio 1.55 1.30 HIVE

Relative Price Performance (Last 90 Days)

HIVE 1M: -28.3% · 3M: -37.2% GEMI 1M: -35.5% · 3M: -36.5%

Current Technical Phase

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -12.4%), weak momentum, RSI 34

RSI (14): 34.3 · Price: $1.72

GEMI

Markdown
Sell / avoid

Price below a falling SMA50 (slope -10.0%), weak momentum, RSI 34

RSI (14): 34.5 · Price: $2.65

Fundamentals Snapshot

Metric HIVE GEMI
Market Cap — —
Forward P/E -3.4 -1.3
Trailing P/E — 0.2
Revenue (TTM) — —
Revenue Growth 0.7% 0.4%
Gross Margin 0.4% -0.3%
Operating Margin -0.6% -1.7%
EPS -1.32 15.01
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.